Khiron Expands Medical Cannabis E-Learning Platform to UK Market

  • UK doctors to receive medical cannabis education through Khiron partnership with Medical Cannabis Clinicians Society (“MCCS”), effective Q3 2020
  • Expands reach of Khiron’s globally recognized cloud-based learning platform currently active in universities and institutions in¬†Latin America
  • MCCS is an independent, clinician-led organization sharing guidance to lead the medical cannabis conversation in the UK
  • Program comprises access to Khiron’s e-learning modules to help doctors prescribe medical cannabis for priority conditions including chronic pain, anxiety, cancer and epilepsy
  • Program accelerates medical cannabis knowledge for doctors participating in Project Twenty21, the UK’s largest medical cannabis registry
  • By 2024, the UK medical cannabis market is predicted to be worth nearly ¬£1bn, servicing nearly 340,000 active patients (source: Prohibition Partners)
Khiron Life Sciences Corp. (CNW Group/Khiron Life Sciences Corp.) (CNW Group/Khiron Life Sciences Corp.)

TORONTO,¬†Aug. 25, 2020¬†/PRNewswire/ –¬†Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in¬†Latin America¬†and¬†Europe, announced that it has signed an agreement with Medical Cannabis Clinicians Society (“MCCS”), an independent, clinician-led organization in the UK. Under this agreement, Khiron will provide medical cannabis knowledge and training through its cloud-based learning platform to participating doctors across the¬†United Kingdom. The agreement is effective immediately, with first education modules underway in Q3, 2020.

“Doctor education continues to be a core mission for Khiron. Through this partnership with MCCS our e-learning program and highly trained medical team will now bring our successful medical cannabis knowledge to UK doctors so that they in turn can better meet patient needs. A lack of doctor education has been missing in growing the UK medical cannabis market and we are pleased to participate in helping the medical community overcome this barrier,” comments¬†Tejinder Virk, Khiron Europe President.

The Khiron medical cannabis program begins with online courses for MCCS participants in Q3, 2020, introducing doctors in the UK to specific regulatory considerations, clinical evidence and research, safety and drug interactions, clinical cases and practical recommendations to best meet patient needs for conditions that include chronic pain, anxiety, cancer and epilepsy. Doctors participating in this program are also members of Project Twenty21, the leading medical cannabis registry in the UK. Khiron is the exclusive LatAm provider of medical cannabis to the project.

In¬†November 2018¬†the UK legalized medical cannabis, establishing a market opportunity to reach and positively impact the lives of a population of over 66 million according to Prohibition Partners UK Report. The UK market opportunity remains large, with more than 1.4 million people in the UK using ‘street’ cannabis for chronic pain alone (Source: Prohibition Partners), and the number of scripts expected to increase as access to medical cannabis expands, and doctors receive more education on suitable applications. By 2024, the UK medical cannabis market is predicted to be worth nearly ¬£1bn, servicing nearly 340,000 active patients (source: Prohibition Partners)

“We know that education is critically important in helping doctors issue safe and effective medical cannabis prescriptions for certain conditions. Partnering with Khiron is invaluable for MCCS in allowing our members to work with the company’s globally validated e-learning platform to inform doctors and to improve the quality of UK patient lives through medical cannabis,” comments Prof.¬†Mike Barnes, Chair, Medical Cannabis Clinicians Society.

SOURCEKhiron Life Sciences Corp.